Concordance between the CC chemokine receptor 5 genetic determinants that alter risks of transmission and disease progression in children exposed perinatally to human immunodeficiency virus

被引:68
作者
Mangano, A
Gonzalez, E
Dhanda, R
Catano, G
Bamshad, M
Bock, A
Duggirala, R
Williams, K
Mummidi, S
Clark, RA
Ahuja, SS
Dolan, MJ
Bologna, R
Sen, L
Ahuja, SK
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Med, Div Infect Dis, San Antonio, TX 78229 USA
[2] Hosp Pediat JP Garrahan, Lab Biol Celular & Retrovirus, Buenos Aires, DF, Argentina
[3] Hosp Pediat JP Garrahan, Serv Infectol, Buenos Aires, DF, Argentina
[4] S Texas Vet Hlth Care Syst, Audie L Murphy Div, Div Infect Dis, San Antonio, TX USA
[5] Wilford Hall USAF Med Ctr, Dept Med, Infect Dis Serv, Lackland AFB, TX 78236 USA
[6] Purdue Pharma, Stamford, CT USA
[7] Univ Utah, Eccles Inst Human Genet, Dept Pediat, Salt Lake City, UT USA
基金
美国国家卫生研究院;
关键词
D O I
10.1086/320705
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
If CC chemokine receptor 5 (CCR5)-dependent mechanisms at the time of initial virus exposure are important determinants of virus entry and disease outcome, then the polymorphisms in CCR5 that influence risk of transmission and disease progression should be similar; this hypothesis was tested in a cohort of 649 Argentinean children exposed perinatally to human immunodeficiency virus type 1 (HIV-1). Two lines of evidence support this hypothesis. First, CCR5 haplotype pairs associated with enhanced risk of transmission were the chief predictors of a faster disease course. Second, some of the haplotype pairs associated with altered rates of transmission and disease progression in children were similar to those that we previously found influenced outcome in European American adults. This concordance suggests that CCR5 haplotypes may serve as genetic rheostats that influence events occurring shortly after initial virus exposure, dictating not only virus entry but, by extension, also the extent of early viral replication.
引用
收藏
页码:1574 / 1585
页数:12
相关论文
共 90 条
[1]   Influence of CCR5 promoter haplotypes on AIDS progression in African-Americans [J].
An, P ;
Martin, MP ;
Nelson, GW ;
Carrington, M ;
Smith, MW ;
Gong, K ;
Vlahov, D ;
O'Brien, SJ ;
Winkler, CA .
AIDS, 2000, 14 (14) :2117-2122
[2]  
[Anonymous], 1998, MMWR Recomm Rep, V47, P1
[3]   Distribution of CCR5Δ32 in human immunodeficiency virus-infected children and its relationship to disease course [J].
Bakshi, SS ;
Zhang, LQ ;
Ho, D ;
Than, S ;
Pahwa, SG .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1998, 5 (01) :38-40
[4]   CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis [J].
Barcellos, LF ;
Schito, AM ;
Rimmler, JB ;
Vittinghoff, E ;
Shih, A ;
Lincoln, R ;
Callier, S ;
Elkins, MK ;
Goodkin, DE ;
Haines, JL ;
Pericak-Vance, MA ;
Hauser, SL ;
Oksenberg, JR .
IMMUNOGENETICS, 2000, 51 (4-5) :281-288
[5]   Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease [J].
Berger, EA ;
Murphy, PM ;
Farber, JM .
ANNUAL REVIEW OF IMMUNOLOGY, 1999, 17 :657-700
[6]   Morbidity and mortality in European children vertically infected by HIV-1 - The French pediatric HIV infection study group and European collaborative study [J].
Blanche, S ;
Newell, ML ;
Mayaux, MJ ;
Dunn, DT ;
Teglas, JP ;
Rouzioux, C ;
Peckham, CS .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1997, 14 (05) :442-450
[7]   Multiple nonfunctional alleles of CCR5 are frequent in various human populations [J].
Blanpain, C ;
Lee, B ;
Tackoen, M ;
Puffer, B ;
Boom, A ;
Libert, F ;
Sharron, M ;
Wittamer, V ;
Vassart, G ;
Doms, RW ;
Parmentier, M .
BLOOD, 2000, 96 (05) :1638-1645
[8]   Genetics of HIV-1 infection: chemokine receptor CCR5 polymorphism and its consequences [J].
Carrington, M ;
Dean, M ;
Martin, MP ;
O'Brien, SJ .
HUMAN MOLECULAR GENETICS, 1999, 8 (10) :1939-1945
[9]   Novel alleles of the chemokine-receptor gene CCR5 [J].
Carrington, M ;
Kissner, T ;
Gerrard, B ;
Ivanov, S ;
O'Brien, SJ ;
Dean, M .
AMERICAN JOURNAL OF HUMAN GENETICS, 1997, 61 (06) :1261-1267
[10]   HLA and HIV-1:: Heterozygote advantage and B*35-Cw*04 disadvantage [J].
Carrington, M ;
Nelson, GW ;
Martin, MP ;
Kissner, T ;
Vlahov, D ;
Goedert, JJ ;
Kaslow, R ;
Buchbinder, S ;
Hoots, K ;
O'Brien, SJ .
SCIENCE, 1999, 283 (5408) :1748-1752